Weight Loss Maintenance Important for Cardiometabolic Risk Control in T2D
A larger percentage of weight loss regained after an intensive lifestyle intervention was positively associated with certain cardiometabolic risk factors in type 2 diabetes.
Type 2 Diabetes
Meta-Analysis: SGLT2 Inhibitors Protect Against Kidney Disease in T2D
A class of diabetes drugs, called sodium-glucose co-transporter-2 inhibitors, protect against kidney disease in patients with type 2 diabetes.
Elevated FGF23 Linked to Mortality in Type 2 Diabetes
In a study, elevated FGF23 was associated with increased risks of major adverse cardiovascular events and mortality in type 2 diabetes patients with normal or mildly impaired kidney function.
Risk Tool Can Predict Heart Failure in Patients With Diabetes
A novel machine learning-derived risk score can predict the risk for heart failure among outpatients with type 2 diabetes.
Increasing Intake of Any Sugary Drink Raises Risk for Diabetes
People who increase their consumption of sweet beverages — either fruit juice or drinks with added sugars — are at greater risk over time for developing diabetes.
Pioglitazone May Reduce Overall Mortality Risk in Patients With Type 2 Diabetes
Findings showed that the combination of insulin and pioglitazone lowered all-cause mortality risk, and this combination therapy exerted beneficial effects on noncardiovascular deaths.
Type 2 Diabetes Prevalent Among People Living With HIV
Approximately 1 in 5 people with HIV also has prevalent DM, and control of hemoglobin A1c levels in these patients may have a beneficial effect on CD4 counts.
IL-1 Inhibition as Targeted Treatment for Rheumatoid Arthritis, Type 2 Diabetes
Researchers investigated the role of interleukin-1 inhibition in improving glycemic and inflammatory parameters in patients with rheumatoid arthritis and type 2 diabetes.
Higher Fat Mass May Increase Risk for Major Adverse CV Events in T2D
In patients with type 2 diabetes, higher fat mass is associated with a higher risk for major adverse cardiovascular events.
Canagliflozin Approved to Slow the Progression of Diabetic Nephropathy in T2D
The FDA has approved a new indication for Invokana (canagliflozin; Janssen) to reduce the risk of end-stage renal disease, doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and diabetic nephropathy with albuminuria >300mg/day.
Next post in Type 2 Diabetes
